Eli Lilly (LLY) announced the upcoming retirement of Anne White, a pivotal figure in its neuroscience division, and entered a ...

A draft copy of an upcoming MAHA report reveals a strategy in lockstep with recent HHS actions such as reviving the Task ...

Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for ...

Now, 15 years of observations have revealed the answer. Using the Very Long Baseline Array, a team led by astronomer Yuri ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Neuroone Medical Technologies Corp. expanded into treatment of chronic pain with a new U.S. FDA clearance for use of its Onerf system to treat trigeminal nerve pain. The system uses radiofrequency ...

Science fiction enriches its stories by inventions like faster-than-light travel. Some are pure fiction, while others are ...

Ball State University has launched its 2025-30 strategic plan that was approved in June. The plan has a long list of goals, including: •All students complete at least one course that involves ...

Eli Lilly (LLY) has signed a $1.3 billion deal with privately held biotechnology firm Superluminal Medicines that will see the two companies employ artificial intelligence (AI) for future drug ...

On Friday, August 15, the stock market had a mixed day. The S&P 500 fell 0.29% after reaching a record high earlier. The Nasdaq Composite dropped by 0.40%.

Shares of Eli Lilly and Company LLY gained 2.7% on reports emerging that a major collaboration deal worth up to $1.3 billion ...

Deal worth up to $1.3 billion brings AI-powered GPCR target discovery into Lilly’s obesity and cardiometabolic pipeline. 2.